Check out this interview with our founder and CEO, Raphael Townshend, which touches upon the need to balance innovation with regulation in #AI, among other interesting topics. Thanks for the engaging conversation, Sanjay Puri!

Our CEO Raphael Townshend sat down recently with Hoover Institute and Stanford experts, policymakers and business leaders + Sec. Condoleezza Rice ! Bio-Strategies and Leadership Holds Inaugural Congressional Fellowship Program on Biotech Strategy | Hoover Inst. t.ly/El0QC

🌐 Heading to #BIOEurope next month? If you’re interested in discussing partnering, our Head of Business Development, Mark Stead, would love to connect with you. Set up a meeting via the event's partneringONE resource: informaconnect.com/bioeurope/part…

We're excited to welcome Pillar VC to the San Francisco stop of the Founder-led Biotech Tour. Join Atomic AI and our fellow SF company co-hosts at this unique gathering of biotech founders, PhDs, investors & leaders.

How will Atomic AI's novel combination of AI and structural biology accelerate #drugdiscovery and overcome some of the current challenges in #drugdevelopment? Founder & CEO Raphael Townshend explains the company's innovative approach with Craig S. Smith of Eye On A.I.: ivoox.com/en/202-raphael…

Heading to Seattle for the AACR special conference on RNAs as Drivers, Targets & Therapeutics in Cancer? Atomic AI CSO Manjunath Ramarao will be participating in the Nov. 17 plenary on Emerging RNA Technologies. Don't miss his 11:30 a.m. presentation! #aacrRNA24

🎉 Exciting news! Atomic AI’s 𝗔𝗧𝗢𝗠-𝟭 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺 has been nominated as one of The Medicine Maker’s standout innovations of 2024! 🌟 🗳️ Voting is open until January—please help us bring this honor home! themedicinemaker.com/manufacture/th…

How will Atomic AI's novel combination of AI and structural biology accelerate #drugdiscovery and overcome some of the current challenges in #drugdevelopment? Founder & CEO Raphael Townshend explains the company's innovative approach with Craig S. Smith of @Eyeon_AI: lnkd.in/eds9dfiN

GREAT NEWS: Atomic AI has been named one of "𝗙𝗶𝘃𝗲 𝗦𝗺𝗮𝗹𝗹 𝗕𝗶𝗼𝘁𝗲𝗰𝗵𝘀 𝘁𝗼 𝗪𝗮𝘁𝗰𝗵." A huge thank you to Pharma's Almanac, as well as our team, partners & supporters. 2025 is going to be a great year! 📰 Check out the full list:  pharmasalmanac.com/articles/five-…

#TBT to #JPM2025, where Atomic AI Founder & CEO Raphael Townshend sat down to discuss how the company is applying AI technologies that have transformed protein #drugdiscovery into the #RNA world, pushing forward a new frontier of RNA targeted medicine design.

Atomic AI is about more than just generative #AI. Listen to Founder & CEO Raphael Townshend explain the company's four-prong approach to transforming RNA #drugdiscovery in this #JPM2025 interview clip. ▶️ Learn more: atomic.ai/technology/

Join me in South San Francisco on April 2 at Biocom California’s Converge Summit where I’ll be participating on the Latest Advancements in Drug Discovery panel. #ConvergeSummit: app.sosha.ai/s/xt4YDdAN

What will it take to unlock the full potential of RNA? In a new nature technology feature, Diana Kwon speaks to our founding scientist Stephan Eismann about how we are pushing the boundaries of RNA structure prediction to design new therapeutics. nature.com/articles/d4158…

Raphael Townshend Raphael Townshend left big tech to build something bigger: Atomic AI . He’s now leading the charge to decode RNA drug discovery with machine learning and structural biology. Catch his talk at #SynBioBeta on May 7 at 2:15 PM in San Jose: “AI x RNA: Foundation Models

We’re heading to Washington, D.C., tomorrow to join policymakers, technologists & industry leaders at the AI+ Biotechnology Summit.  We are excited to be part of the conversation around shaping a national strategy for #AI-driven biotech innovation & security.

In Singapore for #ICLR2025? Be sure to catch the ICLR Nucleic Acids Workshop on Monday, featuring a talk from our head of machine learning, Stephan Eismann. ai4na-workshop.github.io

Could reprogramming RNA splicing to trigger a premature stop codon—and thereby reduce the production of a key cancer-driving protein—unlock a new frontier in cancer treatment? Learn about ATM-5292, an orally available small molecule targeting two key oncogenes, at #AACR25.

“RNA remains a black box—especially structurally. While we know around 7,000 protein structures out of 20,000 in humans, we only have 100 RNA structures out of 100,000 possible transcripts. That gap in understanding is exactly why many algorithms struggle to predict RNA shape.”

Join Raphael Townshend at #SCSPAIExpo2025 on Jun 2nd where industry, academia, and govt come together to explore and demo emerging tech. 10:10 AM – Tech talk on AI + RNA drug design 2:50 PM – Panel on accelerating drug discovery w/AI 🔗 expo.scsp.ai

Join Atomic AI at #BIO2025 in Boston! We’re excited to be part of the panel: 🧬 “Integrating AI-Driven Drug Discovery to Improve R&D Supply Chain Efficiency” 📆 June 16 | 3–4 PM 📍 254B bit.ly/4jvX3TI